Avoro Capital Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Avoro Capital Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,670,000	Closed	-$11.4M	–	43
2022 Q1	$11.4M	Hold	1,670,000	–	–	0.21%	38
2021 Q4	$13.5M	Sell	1,670,000 -605,000	-27%	-$5.53M	0.23%	36
2021 Q3	$22.3M	Sell	2,275,000 -2,090,000	-48%	-$16.5M	0.35%	36
2021 Q2	$29.4M	Hold	4,365,000	–	–	0.51%	31
2021 Q1	$39.5M	Hold	4,365,000	–	–	0.68%	31
2020 Q4	$29.2M	Buy	4,365,000 +165,000	+4%	+$1.03M	0.5%	30
2020 Q3	$21.2M	Sell	4,200,000 -365,655	-8%	-$2.66M	0.3%	35
2020 Q2	$36.9M	Buy	4,565,655 +200,000	+5%	+$1.76M	0.73%	27
2020 Q1	$34.7M	Buy	+4,365,655	New	+$33.5M	1.17%	21
2015 Q3	–	Sell	-267,747	Closed	-$5.67M	–	35
2015 Q2	$5.67M	Buy	267,747 +52,042	+24%	+$933K	1.56%	18
2015 Q1	$3.88M	Buy	215,705 +900	+0.4%	+$14.1K	1.49%	19
2014 Q4	$3.68M	Buy	+214,805	New	+$3.07M	2.49%	15

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Avoro Capital Advisors's AVDL Position: Q2 2022 in Review

Avoro Capital Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 1,670,000 shares — an estimated $11.4M sold.

Avoro Capital Advisors first reported a position in AVDL in Q4 2014 and held it in 12 quarters. The position peaked at $39.5M in Q1 2021. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

Avoro Capital Advisors reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Avoro Capital Advisors sold 1,670,000 Avadel Pharmaceuticals shares in Q2 2022, an estimated $11.4M.
Avoro Capital Advisors first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 12 quarters.
Avoro Capital Advisors's Avadel Pharmaceuticals position peaked at $39.5M in Q1 2021.
82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Avoro Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.